日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway

DNMT2-m5C-ACLY轴通过组蛋白乙酰化介导的Notch通路促进肝细胞癌对乐伐替尼的耐药性

Yang, Shiguang; Li, Jie; Mao, Shengwei; Zhao, Xuhui; Liu, Douwaner; Chen, Jiafeng; Fu, Jialu; Bu, Yichao; Wu, Xiaoling; Liu, Shaoqing; Yu, Qifeng; Dong, Qiongzhu; Tang, Zheng; Fang, Yuan; Shi, Yinghong

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study

一线替雷利珠单抗和奥西哌利单抗联合吉西他滨和顺铂治疗晚期胆道癌(ZSAB-TOP):一项多中心、单臂、II期研究

Shi, Guoming; Huang, Xiaoyong; Ma, Liang; Li, Hui; Zhong, Jianhong; Wang, Junye; Gao, Qiang; Guo, Xiaojun; Qiu, Shuangjian; Sun, Huichuan; Shi, Yinghong; Huang, Xiaowu; Wang, Xiaoying; Yi, Yong; Zhu, Xiaodong; Huang, Cheng; Ding, Zhenbin; Chen, Yi; He, Yifeng; Shen, Yinghao; Sun, Qiman; Zhou, Jian; Fan, Jia

Metabolism archetype cancer cells induce protumor TREM2(+) macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma.

代谢原型癌细胞通过oxLDL介导的代谢相互作用诱导肝细胞癌中的促肿瘤TREM2(+)巨噬细胞

Chu Tianhao, Zhu Guiqi, Tang Zheng, Qu Weifeng, Yang Rui, Pan Haiting, Wang Yi, Tian Ruilin, Chen Leilei, Guan Zhiqi, Bu Yichao, Zhao Qianfu, Chen Jiafeng, Mao Shengwei, Fang Yuan, Gao Jun, Wu Xiaoling, Zhou Jian, Liu Weiren, Ye Dan, Fan Jia, Shi Yinghong

Targeting Deltex E3 Ubiquitin Ligase 2 Inhibits Tumor-associated Neutrophils and Sensitizes Hepatocellular Carcinoma Cells to Immunotherapy

靶向 Deltex E3 泛素连接酶 2 可抑制肿瘤相关中性粒细胞并增强肝细胞癌细胞对免疫疗法的敏感性

Wu, Xiaoling; Chen, Jiafeng; Chen, Yiran; Song, Shushu; Fang, Yuan; Mao, Shengwei; Gao, Jun; Zhu, Guiqi; Qu, Weifeng; Zhao, Qianfu; Yang, Rui; Guan, Zhiqi; Chu, Tianhao; Bu, Yichao; Wang, Yi; Chen, Fangyu; Zhou, Jian; Fan, Jia; Tang, Zheng; Liu, Weiren; Ruan, Yuanyuan; Shi, Yinghong

Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma

靶向 CREB3L2 介导的脂质代谢可克服乐伐替尼耐药性并减缓肝细胞癌的进展。

Yang, Shiguang; Liu, Shaoqing; Li, Jie; Mao, Shengwei; Yu, Qifeng; Zhao, Xuhui; Wu, Xiaoling; Chen, Jiafeng; Bu, Yichao; Liu, Weiren; Fang, Yuan; Shi, Yinghong

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)

中国肝癌诊疗指南(2024版)

Zhou, Jian; Sun, Huichuan; Wang, Zheng; Cong, Wenming; Zeng, Mengsu; Zhou, Weiping; Liu, Lianxin; Wen, Tianfu; Kuang, Ming; Zhang, Bixiang; Tao, Kaishan; Han, Guohong; Yan, Zhiping; Wang, Maoqiang; Liu, Ruibao; Guo, Jinhe; Zeng, Zhaochong; Liang, Ping; Ren, Zhenggang; Hou, Jinlin; Zhang, Yanqiao; Liu, Xiufeng; Pan, Hongming; Bi, Feng; Liang, Changhong; Chen, Min; Yan, Fuhua; Xu, Huixiong; Xie, Xiaoyan; Ju, Shenghong; Ji, Yuan; Yun, Jingping; Li, Zengshan; Bai, Xueli; Cai, Dingfang; Chen, Weixia; Chen, Yajin; Chen, Yongjun; Cheng, Wenwu; Cheng, Shuqun; Dai, Zhi; Dai, Chaoliu; Gao, Qiang; Guo, Rongping; Guo, Wengzhi; Guo, Yabing; Hua, Baojin; Huang, Xiaowu; Jiang, Hanyu; Jia, Weidong; Li, Qiu; Li, Tao; Li, Xiangcheng; Li, Xun; Li, Yaming; Li, Yexiong; Liang, Jun; Liang, Xiao; Ling, Changquan; Liu, Hui; Liu, Tianshu; Lu, Shichun; Lv, Guoyue; Mao, Yilei; Meng, Zhiqiang; Peng, Tao; Ren, Weixin; Shi, Guoming; Shi, Hongcheng; Shi, Ming; Song, Tianqiang; Tan, Guang; Wang, Jianhua; Wang, Kui; Wang, Lu; Wang, Wentao; Wang, Xiaoying; Wang, Zhiming; Xiang, Bangde; Xia, Jun; Xing, Baocai; Xu, Jianming; Xu, Jun; Yang, Jianyong; Yang, Xinrong; Yang, Yefa; Yang, Yunke; Yao, Xiaohong; Yin, Zhenyu; Yuan, Zhengang; Zeng, Yongyi; Zeng, Yong; Zhang, Boheng; Zhang, Leida; Zhang, Shuijun; Zhang, Ti; Zhang, Zhiwei; Zhao, Ming; Zhao, Yongfu; Zheng, Honggang; Zhou, Ledu; Zhu, Jiye; Zhu, Kangshun; Shi, Yinghong; Liu, Rong; Zhang, Lan; Xiao, Yongsheng; Yang, Chun; Wu, Zhifeng; Ding, Zhengbin; Zhu, Xiaodong; Tang, Zheng; Huang, Xiaoyong; Han, Hong; Wu, Hong; Chen, Minshan; Wang, Weilin; Li, Qiang; Cai, Jianqiang; Shen, Feng; Cai, Xiujun; Qin, Shukui; Teng, Gaojun; Fan, Jia

Auxiliary liver transplantation using otherwise-discarded liver allograft combined with associating liver partition and portal vein ligation for staged hepatectomy for unresectable colorectal liver metastases

对于无法切除的结直肠癌肝转移,可采用辅助性肝移植术,利用原本将被丢弃的肝脏同种异体移植片,并结合肝脏分割和门静脉结扎术进行分期肝切除。

Wang, Zheng; Huang, Xiaowu; Shi, Yinghong; Wang, Xiaoying; Ding, Zhenbin; Xiao, Yongsheng; He, Yifeng; Wang, Ting; Sun, Jian; Song, Kang; Shen, Zaozhuo; Yu, Lei; Zhu, Kai; Miao, Changhong; Ji, Yuan; Yang, Liuxiao; Hou, Yingyong; Gao, Qiang; Fan, Jia; Zhou, Jian

Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity.

免疫代谢物 L-2-HG 促进耗竭 T 细胞的表观遗传修饰,并提高抗肿瘤免疫力

Yang Yanying, Li Xiaoyan, Liu Fangming, Ma Mingyue, Yang Ying, Ruan Chengchao, Lu Yan, Li Xiaoyang, Wang Xiangdong, Shi Yinghong, Zhang Zheng, Wang Hua, Cheng Zhouli, Wu Duojiao

Landscape analysis of m5C modification regulators unveils DNMT1-mediated dysregulated pyrimidine metabolism in hepatocellular carcinoma

m5C修饰调控因子的景观分析揭示了DNMT1介导的肝细胞癌中嘧啶代谢紊乱

Zhao, Xuhui; Mao, Shengwei; Fang, Yuan; Chen, Jiafeng; Bi, Lifu; Li, Jie; Wu, Jinglei; Gao, Jun; Yang, Shiguang; Fu, Jialu; Wu, Xiaoling; Zhu, Guiqi; Tang, Zheng; Shi, Yinghong; Zhou, Jian; Fan, Jia; Zhang, Xingxing; Jiang, Jinling; Liu, Weiren

Duration of hepatic portal occlusion is a valuable predictor for postoperative nausea and vomiting in patients underwent liver resection for liver cancer

肝门静脉阻塞持续时间是肝癌切除术后患者术后恶心呕吐的重要预测指标。

Chen, Xiao; Zhao, Wen Juan; Yu, Jingxian; Zhou, Haiying; Shi, Yinghong; Gao, Jian; Zhang, Yuxia